Advisor Group’s Dianthus Therapeutics DNTH Stock Holding History

Advisor Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12	Closed	-$2K	–	5127
2018 Q3	$2K	Buy	+12	New	+$2.53K	﹤0.01%	4840

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Advisor Group's DNTH Position: Q4 2018 in Review

Advisor Group sold out of Dianthus Therapeutics (DNTH) in Q4 2018, closing a stake of 12 shares — an estimated $2K sold.

Advisor Group first reported a position in DNTH in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 54 funds tracked by Wall St. Rank hold DNTH as of Q4 2018.

Advisor Group reported no remaining Dianthus Therapeutics position as of Q4 2018 after selling out during the quarter.
Advisor Group sold 12 Dianthus Therapeutics shares in Q4 2018, an estimated $2K.
Advisor Group first reported a position in Dianthus Therapeutics in Q3 2018 and held it in 1 quarter.
Advisor Group's Dianthus Therapeutics position peaked at $2K in Q3 2018.
54 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2018.

Based on Advisor Group's 13F filing for Q4 2018, filed 11 Feb 2019.